Overview

Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
300 patients, starting a new pharmacological treatment for B-CLL, were enrolled by 36 Italian Centres for assessing the Quality of Life (QoL). A descriptive analysis of QoL and the correlation of the age, sex, stage of disease, Time from first B-CLL diagnosis, Number of previous B-CLL treatments, reason of starting of the new B-CLL treatment: therapeutic Regimen, type of Centre, B-CLL treatment lasting, response to B-CLL treatment.
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Alemtuzumab
Fludarabine
Fludarabine phosphate